Apnimed has announced The Lancet has published positive results from the Phase 2 FLOW study evaluating sulthiame, a differentiated, once-daily oral carbonic anhydrase inhibitor, in the treatment of ...
A comprehensive review published today in Brain Medicine illuminates the intricate connections between gut microbiota and sleep regulation, establishing the microbiota-gut-brain axis as a critical ...
Moderate-to-severe obstructive sleep apnea is linked to a doubling in 8-year risk for cerebral microbleeds in middle-aged and ...
GEM SLEEP, a provider of fully virtual sleep apnea care from at-home testing and diagnosis through treatment setup and ongoing support, announced a set of new product enhancements designed to further ...
12hon MSN
If you woke up wanting to stay in bed Monday morning, it may not be due to daylight savings
Dr. Meena Khan with the Ohio State University Wexner Medical Center says there are several ways to treat obstructive sleep ...
A new guideline published by the American Academy of Sleep Medicine in the Journal of Clinical Sleep Medicine is the first to provide recommendations for the management of obstructive sleep apnea in ...
Apnimed, Inc., a pharmaceutical company building the industry-leading portfolio of first-in-class oral drug candidates that address the root causes of obstructive sleep apnea (OSA) and other ...
The Company is scheduled to present at 9:20am Eastern Time the same day via webcast. A live webcast of the event can be ...
Gross margin was 85.8% for the third quarter of 2025 compared to 84.1% in the third quarter of 2024. The year-over-year increase was due to higher sales volume and higher Inspire V sales mix, which ...
Meanwhile, beta blocker medications tend to reduce REM sleep, which is when most dreaming occurs, but research has found that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback